A strong team with experience and know-how


Dr. Walter von Horstig - Vorstand
Dr. Walter von Horstig

Dr. Walter von Horstig

Dr. von Horstig studied business administration at the University of Mannheim and St. Gall, where he also completed his PhD thesis. From 1993 to 1998 he worked as a management consultant for Bain & Company and the ABB Group. From 1999 to 2004, Dr. von Horstig was founder, managing director and board member of several start-up companies in the service and biotech sector, before joining the Underberg Group as Commercial Director. From 2009 to the beginning of 2017, Dr. von Horstig was the Managing Director of a DRK blood donation service and was responsible for a fundamental economic restructuring of the company. In April 2017, he joined the M1 Med Beauty Berlin GmbH as Managing Director before being appointed to the Management Board of M1 Kliniken AG in October 2017.


Dr. Albert Wahl
Uwe Zimdars
Prof. Dr. Dr. Sabine Meck

Latest news

| Investor News

  • Group revenue rises to just under EUR 165 million (EUR 37 million in H1-
  • Consolidated EBITDA amounts to EUR 9.9 million (previous year: EUR 1.7
    million); EBIT amounts to EUR 7.1 million (previous year: EUR -0.05
  • Beauty: Significant increase in treatment and sales figures; Coronarelated
    ‘idle capacity’ due to vaccination intervals

| Investor News

After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future.

| Investor News

M1 Kliniken AG announces figures for the first quarter of 2021. According to these figures, the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx. 250% year-on-year to just under EUR 81 million (previous year: EUR 23 million). Of this, HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of a good EUR 59 million.

| Investor News

M1 Kliniken AG publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.